Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICAASO: Dasatinib alone or with Darolutamide in Metastatic Prostate Cancer
NCT04925648Phase 2Completed
- Sponsor
- St Vincent's Hospital
- Start
- Oct 2021
- Primary completion
- Sep 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of dasatinib in metastatic castration-resistant prostate cancer (mCRPC) (2 cohorts), sponsored by St Vincent's Hospital. Primary endpoint: Increase in tumour standard uptake value (SUV) measurements at 14 days. Started Oct 2021; status: completed.
02
Drugs
dasatinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04925648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925648.